Drug Approval | October 20, 2021
FDA approves Cyltezo, the first interchangeable biosimilar to Humira
Second interchangeable biosimilar product approved by agency
Second interchangeable biosimilar product approved by agency
The division is expected to grow to over a 100-member strong team by 2022
Rajiv Gandhi Cancer Institute (RGCI), Delhi one of Asia’s premier institutes becomes the first strategic partner to adopt and implement Project Chariot in patients across North India & Delhi NCR region
ICICI Direct gives an update on the 12 companies that it has covered in the healthcare universe. A report
Drugs and pharmaceuticals were among the top eight export items in H1FY22, according to a Care Ratings report.
The company claims that its Empagliflozin tablets are the most affordable in India
_256_384.jpg)
The platform will be a curated marketplace for sustainable-driven products by small-medium entrepreneurs and will encourage an autonomous marketplace
Ipsen obtains an exclusive license to develop, manufacture and commercialize a pre-clinical stage METTL3-inhibitor programme
The company operates four mid-sized hospitals with a total bed capacity of 556 in eastern India
The survey revealed that improving customer experience (CX) and operational efficiencies are top priorities, which healthcare organizations aim to attain by deploying digital health solutions
Subscribe To Our Newsletter & Stay Updated
